Mанитол Биофарм (Mannitol)

Mannitol acts as an osmotic agent. After intravenous infusion, it stays in the extracellular fluid, increasing plasma osmolality. This draws water from cells and interstitial spaces into the bloodstream, expanding plasma volume, reducing cerebral edema, and stimulating kidney filtration to produce a diuretic effect.

The dose of mannitol is individualized by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goal. Healthcare professionals calculate the appropriate infusion rate and total amount according to established clinical guidelines.

The safety of mannitol in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mannitol is a widely used osmotic diuretic with a rapid onset of action and predictable renal clearance. Compared with hypertonic saline, mannitol provides both volume expansion and diuresis, making it suitable for managing cerebral edema and renal toxin clearance, whereas hypertonic saline primarily expands intravascular volume without a diuretic effect.

Mанитол Биофарм should be stored at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze the solution.

The product is supplied as a sterile injectable solution for intravenous infusion. Administration is performed by qualified healthcare personnel, typically via a peripheral or central venous line, using an infusion pump or controlled drip to achieve the prescribed rate.

Serious risks include severe electrolyte disturbances such as hypernatremia or hypokalemia, worsening renal function in susceptible patients, pulmonary edema from fluid overload, and rare anaphylactoid reactions. Continuous monitoring of electrolytes, renal function, and fluid status is essential during treatment.

Mannitol is contraindicated in patients with known hypersensitivity to mannitol, severe dehydration, active intracranial bleeding, uncontrolled heart failure, or severe renal impairment where diuresis could exacerbate the condition. Clinicians must evaluate each patient’s medical history before initiating therapy.